256 related articles for article (PubMed ID: 26692274)
1. New Inhaled Antimicrobial Formulations for Use in the Cystic Fibrosis Patient Population.
Campbell CT; McCaleb R; Manasco KB
Ann Pharmacother; 2016 Feb; 50(2):133-40. PubMed ID: 26692274
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis.
Elborn JS; Vataire AL; Fukushima A; Aballea S; Khemiri A; Moore C; Medic G; Hemels ME
Clin Ther; 2016 Oct; 38(10):2204-2226. PubMed ID: 27692977
[TBL] [Abstract][Full Text] [Related]
3. Inhaled liposomal amikacin.
Waters V; Ratjen F
Expert Rev Respir Med; 2014 Aug; 8(4):401-9. PubMed ID: 24882271
[TBL] [Abstract][Full Text] [Related]
4. Aerosolized antibiotics in cystic fibrosis: an update.
Fiel SB
Expert Rev Respir Med; 2014 Jun; 8(3):305-14. PubMed ID: 24838090
[TBL] [Abstract][Full Text] [Related]
5. Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes.
Pesaturo KA; Horton ER; Belliveau P
Ann Pharmacother; 2012; 46(7-8):1076-85. PubMed ID: 22764322
[TBL] [Abstract][Full Text] [Related]
6. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.
Máiz L; Girón RM; Olveira C; Quintana E; Lamas A; Pastor D; Cantón R; Mensa J
Expert Opin Pharmacother; 2013 Jun; 14(9):1135-49. PubMed ID: 23586963
[TBL] [Abstract][Full Text] [Related]
7. Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis.
Antoniu S
Expert Rev Anti Infect Ther; 2015 Jul; 13(7):897-905. PubMed ID: 25921312
[TBL] [Abstract][Full Text] [Related]
8. [Use of inhaled tobramycin in patients with cystic fibrosis].
Chermenskiĭ AG; Gembitskaia TE
Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
[TBL] [Abstract][Full Text] [Related]
9. Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes.
Dasenbrook EC; Konstan MW; VanDevanter DR
J Cyst Fibros; 2015 May; 14(3):370-5. PubMed ID: 25496726
[TBL] [Abstract][Full Text] [Related]
10. Inhaled antibiotics in cystic fibrosis: a review.
Toso C; Williams DM; Noone PG
Ann Pharmacother; 1996; 30(7-8):840-50. PubMed ID: 8826569
[TBL] [Abstract][Full Text] [Related]
11. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Bilton D; Pressler T; Fajac I; Clancy JP; Sands D; Minic P; Cipolli M; Galeva I; Solé A; Quittner AL; Liu K; McGinnis JP; Eagle G; Gupta R; Konstan MW;
J Cyst Fibros; 2020 Mar; 19(2):284-291. PubMed ID: 31451351
[TBL] [Abstract][Full Text] [Related]
12. The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis.
Emiralioglu N; Yalcin E; Meral A; Sener B; Dogru D; Ozcelik U; Kiper N
J Clin Pharm Ther; 2016 Aug; 41(4):419-23. PubMed ID: 27311742
[TBL] [Abstract][Full Text] [Related]
13. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
[TBL] [Abstract][Full Text] [Related]
14. Chronic inhaled antibiotic therapy in people with cystic fibrosis with Pseudomonas aeruginosa infection in Germany.
Naehrig S; Schulte-Hubbert B; Hafkemeyer S; Hammermann J; Dumke M; Sieber S; ; Naehrlich L
Pulm Pharmacol Ther; 2023 Jun; 80():102214. PubMed ID: 37003541
[TBL] [Abstract][Full Text] [Related]
15. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
Hansen C; Skov M
Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692
[TBL] [Abstract][Full Text] [Related]
16. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.
Flume PA; VanDevanter DR; Morgan EE; Dudley MN; Loutit JS; Bell SC; Kerem E; Fischer R; Smyth AR; Aaron SD; Conrad D; Geller DE; Elborn JS
J Cyst Fibros; 2016 Jul; 15(4):495-502. PubMed ID: 26852040
[TBL] [Abstract][Full Text] [Related]
17. Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.
Ehsan Z; Clancy JP
Future Microbiol; 2015; 10(12):1901-12. PubMed ID: 26573178
[TBL] [Abstract][Full Text] [Related]
18. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Greally P; Whitaker P; Peckham D
Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
[TBL] [Abstract][Full Text] [Related]
19. Aztreonam lysine for inhalation: new formulation of an old antibiotic.
Zeitler K; Salvas B; Stevens V; Brown J
Am J Health Syst Pharm; 2012 Jan; 69(2):107-15. PubMed ID: 22215356
[TBL] [Abstract][Full Text] [Related]
20. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
